Certara™, a leading provider of software and scientific consulting
services to improve productivity and decision-making from drug discovery
through drug development, today announced that Professor Geoff
Tucker, its vice president of translational sciences and co-founder
of Simcyp™ and head of its consultancy, has been named president-elect
of the International Society for the Study of Xenobiotics (ISSX).
Established in 1981, ISSX is one of the largest scientific organizations
serving researchers studying the disposition of xenobiotics in
biological systems. Xenobiotics are compounds that are not found
naturally in an organism. They can include drugs, agricultural and
industrial chemicals, food additives, and environmental contaminants.
Many of ISSX's activities are related to drug development and
toxicology. The society has 1,600 members from more than 50 countries.
Professor Tucker assumes the role of ISSX present-elect in 2014, and
will become president in January 2015. He previously served two terms as
an ISSX councilor from 198 to 1991 and from 2004 to 2011.
"I am honored to have been elected by my colleagues to this prestigious
position. I have always been a strong proponent of ISSX because the
society affords outstanding opportunities to share knowledge with and
learn from experts in parallel fields. I plan to partner with other
members of ISSX's leadership team to create new initiatives and to
extend further the society's global reach," said Tucker.
Professor Tucker's areas of expertise include pharmacokinetics, drug
metabolism, pharmacogenetics, and the pharmacology of anesthetic drugs.
An active academic leader, Professor Tucker has served as chairman of
the editorial board of the British Journal of Clinical Pharmacology
and vice president of the International Federation of Pharmaceutical
Sciences. He is a senate member of the European Federation of
Pharmaceutical Sciences and a founding member and elder of the African
Society for Drug Metabolism and Development.
Professor Tucker is Emeritus Professor of Clinical Pharmacology at the
University of Sheffield, England and chair of the Board of
Pharmaceutical Sciences of the International Pharmaceutical Federation.
He has a Ph.D. from the University of London, England and an honorary
D.Sc. from the University of Uppsala, Sweden.
is dedicated to improving human health by delivering a broad spectrum of
software products and consulting services, spanning molecular discovery
to clinical development, with special focus on supporting translational
approaches to drug development. A leading provider of model-based drug
development tools, Certara was formed by the acquisition and integration
of industry leaders Tripos®, Simcyp™, and Pharsight® Corporation. Each
Certara family brand focuses on a key phase within the drug discovery
and development process; combined, they offer a unique set of scientific
modeling, analysis, and simulation capabilities that can enable the
cross-disciplinary approaches necessary for translational science
initiatives. For more information, visit www.certara.com.
[ Back To NFVZone's Homepage ]